Tranexamic acid for significant traumatic brain injury (The CRASH-3 trial): Statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial

Ian Roberts, Antonio Belli, Amy Brenner, Rizwana Chaudhri, Bukola Fawole, Tim Harris, Rashid Jooma, Abda Mahmood, Temitayo Shokunbi, Haleema Shakur, CRASH-3 trial collaborators, Ian Roberts, Antonio Belli, Amy Brenner, Rizwana Chaudhri, Bukola Fawole, Tim Harris, Rashid Jooma, Abda Mahmood, Temitayo Shokunbi, Haleema Shakur, CRASH-3 trial collaborators

Abstract

Background: Worldwide, traumatic brain injury (TBI) kills or hospitalises over 10 million people each year. Early intracranial bleeding is common after TBI, increasing the risk of death and disability. Tranexamic acid reduces blood loss in surgery and death due to bleeding in trauma patients with extra-cranial injury. Early administration of tranexamic acid in TBI patients might limit intracranial bleeding, reducing death and disability. The CRASH-3 trial aims to provide evidence on the effect of tranexamic acid on death and disability in TBI patients. We will randomly allocate about 13,000 TBI patients (approximately 10,000 within 3 hours of injury) to an intravenous infusion of tranexamic acid or matching placebo in addition to usual care. This paper presents a protocol update (version 2.1) and statistical analysis plan for the CRASH-3 trial. Results: The primary outcome is head injury death in hospital within 28 days of injury for patients treated within 3 hours of injury (deaths in patients treated after 3 hours will also be reported). Because there are reasons to expect that tranexamic acid will be most effective in patients treated immediately after injury and less effective with increasing delay, the effect in patients treated within one hour of injury is of particular interest. Secondary outcomes are all-cause and cause-specific mortality, vascular occlusive events, disability based on the Disability Rating Scale and measures suggested by patient representatives, seizures, neurosurgical intervention, neurosurgical blood loss, days in intensive care and adverse events. Sub-group analyses will examine the effect of tranexamic acid on head injury death stratified by time to treatment, severity of TBI and baseline risk. Conclusion: The CRASH-3 trial will provide reliable evidence of the effectiveness and safety of tranexamic acid in patients with acute TBI. Registration: International Standard Randomised Controlled Trials registry ( ISRCTN15088122) 19/07/2011, and ClinicalTrials.gov ( NCT01402882) 25/07/2011.

Keywords: Antifibrinolytic; clinical trial; intracranial bleeding; tranexamic acid; traumatic brain injury.

Conflict of interest statement

No competing interests were disclosed.

Figures

Figure 1.. Relationship between baseline prognostic variables…
Figure 1.. Relationship between baseline prognostic variables (dilated pupils, GCS, blood pressure and age) and time to treatment in hours.
Based on blinded data on approximately 10,000 patients from the CRASH-3 trial.

References

    1. Peden M, McGee K, Sharma G: The injury chart book: A graphical overview of the global burden of injuries.Geneva: World Health Organization;2002.
    1. Bruns J, Jr, Hauser WA: The epidemiology of traumatic brain injury: a review. Epilepsia. 2003;44(s10):2–10. 10.1046/j.1528-1157.44.s10.3.x
    1. Haagsma JA, Graetz N, Bolliger I, et al. : The global burden of injury: incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013. Inj Prev. 2016;22(1):3–18. 10.1136/injuryprev-2015-041616
    1. Perel P, Roberts I, Bouamra O, et al. : Intracranial bleeding in patients with traumatic brain injury: a prognostic study. BMC Emerg Med. 2009;9:15. 10.1186/1471-227X-9-15
    1. Oertel M, Kelly DF, McArthur D, et al. : Progressive hemorrhage after head trauma: predictors and consequences of the evolving injury. J Neurosurg. 2002;96(1):109–16. 10.3171/jns.2002.96.1.0109
    1. Narayan RK, Maas AI, Servadei F, et al. : Progression of traumatic intracerebral hemorrhage: a prospective observational study. J Neurotrauma. 2008;25(6):629–39. 10.1089/neu.2007.0385
    1. Homnick A, Sifri Z, Yonclas P, et al. : The temporal course of intracranial haemorrhage progression: how long is observation necessary? Injury. 2012;43(12):2122–5. 10.1016/j.injury.2012.04.013
    1. Harhangi BS, Kompanje EJ, Leebeek FW, et al. : Coagulation disorders after traumatic brain injury. Acta Neurochir (Wien). 2008;150(2):165–75; discussion 75. 10.1007/s00701-007-1475-8
    1. Bayir A, Kalkan E, Koçak S, et al. : Fibrinolytic markers and neurologic outcome in traumatic brain injury. Neurol India. 2006;54(4):363–5. 10.4103/0028-3886.28106
    1. Ker K, Prieto-Merino D, Roberts I: Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss. Br J Surg. 2013;100(10):1271–9. 10.1002/bjs.9193
    1. CRASH-2 Collaborators, Shakur H, Roberts I, et al. : Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23–32. 10.1016/S0140-6736(10)60835-5
    1. CRASH-2 Collaborators, Roberts I, Shakur H, et al. : The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096–101, 101 e1-2. 10.1016/S0140-6736(11)60278-X
    1. WOMAN Trial Collaborators: Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105–16. 10.1016/S0140-6736(17)30638-4
    1. Gayet-Ageron A, Prieto-Merino D, Ker K, et al. : Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet. 2018;391(10116):125–132. 10.1016/S0140-6736(17)32455-8
    1. Dewan Y, Komolafe EO, Mejia-Mantilla JH, et al. : CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials. 2012;13:87. 10.1186/1745-6215-13-87
    1. Mahmood A, Roberts I, Shakur H: A nested mechanistic sub-study into the effect of tranexamic acid versus placebo on intracranial haemorrhage and cerebral ischaemia in isolated traumatic brain injury: study protocol for a randomised controlled trial (CRASH-3 Trial Intracranial Bleeding Mechanistic Sub-Study [CRASH-3 IBMS]). Trials. 2017;18(1):330. 10.1186/s13063-017-2073-6
    1. Roberts I, Prieto-Merino D, Manno D: Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial. Crit Care. 2014;18(6):685. 10.1186/s13054-014-0685-8
    1. Raza I, Davenport R, Rourke C, et al. : The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013;11(2):307–14. 10.1111/jth.12078
    1. Liras IN, Cotton BA, Cardenas JC, et al. : Prevalence and impact of admission hyperfibrinolysis in severely injured pediatric trauma patients. Surgery. 2015;158(3):812–8. 10.1016/j.surg.2015.05.004
    1. Chapman MP, Moore EE, Moore HB, et al. : Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients. J Trauma Acute Care Surg. 2016;80(1):16–23; discussion 23–5. 10.1097/TA.0000000000000885
    1. Wu X, Darlington DN, Cap AP: Procoagulant and fibrinolytic activity after polytrauma in rat. Am J Physiol Regul Integr Comp Physiol. 2016;310(4):R323–9. 10.1152/ajpregu.00401.2015
    1. Moore EE, Moore HB, Gonzalez E, et al. : Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid. J Trauma Acute Care Surg. 2015;78(6 Suppl 1):S65–9. 10.1097/TA.0000000000000634
    1. Epstein DS, Mitra B, O'Reilly G, et al. : Acute traumatic coagulopathy in the setting of isolated traumatic brain injury: a systematic review and meta-analysis. Injury. 2014;45(5):819–24. 10.1016/j.injury.2014.01.011
    1. Abdelmalik PA, Boorman DW, Tracy J, et al. : Acute Traumatic Coagulopathy Accompanying Isolated Traumatic Brain Injury is Associated with Worse Long-Term Functional and Cognitive Outcomes. Neurocritical Care. 2016;24(3):361–70. 10.1007/s12028-015-0191-0
    1. Folkerson LE, Sloan D, Cotton BA, et al. : Predicting progressive hemorrhagic injury from isolated traumatic brain injury and coagulation. Surgery. 2015;158(3):655–61. 10.1016/j.surg.2015.02.029
    1. Nakae R, Yokobori S, Takayama Y, et al. : Age-related differences in fibrinolytic parameters in patients with acute traumatic brain injury. Surg Neurol Int. 2017;8:214.
    1. Haybittle JL: Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol. 1971;44(526):793–7. 10.1259/0007-1285-44-526-793
    1. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S: Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet.2010;376(9734) : 10.1016/S0140-6736(10)60835-5 23-32 10.1016/S0140-6736(10)60835-5
    1. Maas AIR, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, Bragge P, Brazinova A, Büki A, Chesnut RM, Citerio G, Coburn M, Cooper DJ, Crowder AT, Czeiter E, Czosnyka M, Diaz-Arrastia R, Dreier JP, Duhaime AC, Ercole A, van Essen TA, Feigin VL, Gao G, Giacino J, Gonzalez-Lara LE, Gruen RL, Gupta D, Hartings JA, Hill S, Jiang JY, Ketharanathan N, Kompanje EJO, Lanyon L, Laureys S, Lecky F, Levin H, Lingsma HF, Maegele M, Majdan M, Manley G, Marsteller J, Mascia L, McFadyen C, Mondello S, Newcombe V, Palotie A, Parizel PM, Peul W, Piercy J, Polinder S, Puybasset L, Rasmussen TE, Rossaint R, Smielewski P, Söderberg J, Stanworth SJ, Stein MB, von Steinbüchel N, Stewart W, Steyerberg EW, Stocchetti N, Synnot A, Te Ao B, Tenovuo O, Theadom A, Tibboel D, Videtta W, Wang KKW, Williams WH, Wilson L, Yaffe K., InTBIR Participants and Investigators: Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol.2017;16(12) : 10.1016/S1474-4422(17)30371-X 987-1048 10.1016/S1474-4422(17)30371-X
    1. Gupta D, Sharma D, Kannan N, Prapruettham S, Mock C, Wang J, Qiu Q, Pandey RM, Mahapatra A, Dash HH, Hecker JG, Rivara FP, Rowhani-Rahbar A, Vavilala MS: Guideline Adherence and Outcomes in Severe Adult Traumatic Brain Injury for the CHIRAG (Collaborative Head Injury and Guidelines) Study. World Neurosurg.89: 10.1016/j.wneu.2015.12.097 169-79 10.1016/j.wneu.2015.12.097

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa